Idun Pharmaceuticals relocates to San Diego
New 43,000-square-foot facility provides expanded lab space for drug discovery, development
Idun Pharmaceuticals Inc. (San Diego) has completed its move to a new 43,000-square-foot facility in San Diego, California, the company announced today. For the last five years, the company was located in nearby La Jolla.
"The new facility includes state-of-the-art research labs for chemistry and biology research as well as product development activities," Idun president Steven Mento stated in a company press release. "This will accommodate our company's growth and allow us to accelerate our development programs in cardiovascular, liver disease, stroke, cancer, and inflammation.''
Idun's enzymology, high-throughput screening, chemistry, and molecular and cell biology groups will all have expanded lab space in the new building. The site also features increased cell culture and vivarium capabilities, and offers room for future growth, particularly for Idun's growing apoptosis discovery and drug development programs.
"We have important ongoing collaborations with Abbott Laboratories in cancer and Elan Pharmaceuticals in stroke in addition to our rapidly moving internal programs in liver and cardiovascular diseases, and inflammation," said Kevin Tomaselli, vice president of discovery research at Idun. "The new facility will allow our scientists to maximize their efforts in a state-of-the-art facility."
Idun Pharmaceuticals Inc. is a biopharmaceutical company that creates human therapeutics with a primary focus on controlling apoptosis, or programmed cell death. Idun believes that controlling the cell death process will have utility in treating cancer, neurodegenerative diseases, ischemic disorders, and cardiovascular disease.
For more information: Steven J. Mento, President and CEO, Idun Pharmaceuticals Inc., 9380 Judicial Dr., San Diego, CA 92121. Tel: 858-623-1330.
With contributions from Jim Pomager
Assistant Editor, Pharmaceutical Online
Source: Idun Pharmaceuticals Inc.